Candel Therapeutics, Inc. CADL
Candel Therapeutics, Inc. (Nasdaq: CADL) is an oncology drug developer. Its lead program, aglatimagene besadenovec (CAN-2409) plus valacyclovir, is in Phase 3 for Localized intermediate/high-risk prostate cancer (completed Phase 3, positive topline); metastatic non-squamous NSCLC (Phase 3 AURORA enrolling). Its next catalyst on record is Linoserpaturev: Presentation of data on potential long-term survivors (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: Linoserpaturev — Presentation of data on potential long-term survivors (Q4 2026). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Aglatimagene besadenovec, prostate cancer Phase 3 (SPA) | Newly diagnosed localized intermediate/high-risk prostate cancer with radiation therapy | gene therapy | Phase 3 |
| Aglatimagene besadenovec, AURORA Phase 3 | Metastatic stage IV non-squamous NSCLC progressing on ICI, vs docetaxel | gene therapy | Phase 3 |
| Aglatimagene besadenovec, prostate Phase 2a biomarker/biodistribution study | Localized intermediate-risk prostate cancer | gene therapy | Phase 2 |
| Aglatimagene besadenovec, NSCLC Phase 2a | Stage III/IV NSCLC with inadequate response to PD-(L)1 inhibitors | gene therapy | Phase 2 |
| Aglatimagene besadenovec, pancreatic cancer Phase 2a | Borderline resectable PDAC (completed; further development paused October 2025 unless externally funded) | gene therapy | Phase 2 |
| Linoserpaturev (CAN-3110) | Recurrent high-grade glioma (investigator-sponsored Phase 1b; IND cleared January 2026 for planned randomized Phase 2 dose-regimen study) | gene therapy | Phase 1 |
| enLIGHTEN-derived candidates (Alpha-201 Macro1 and others) | Solid tumors | gene therapy | Pre-clinical |
Recent results and decisions
- May 15, 2026met Extended follow-up (median 58 months): prostate cancer-specific DFS improved 39% vs placebo (HR 0.61, p=0.0031); secondary endpoints directionally favorable but not significant.
aglatimagene arm exhibited a 39% improvement in prostate cancer-specific disease-free survival (PCa-specific DFS) compared to placebo (hazard ratio [HR] 0.61; 95% confidence interval [CI]: 0.44, 0.85; p=0.0031)
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 oncology companies
- Merck & Co., Inc. MRK
- Astrazeneca PLC AZN
- Bristol Myers Squibb Co BMY
- BeOne Medicines Ltd. ONC
- Revolution Medicines, Inc. RVMD
- Genmab A/S GMAB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.